pembrolizumab, sabr develop a rapport for oligometastatic rcc | shankar siva
Published 3 years ago • 192 plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
3:03
adjuvant pembrolizumab improves rcc disease-free survival | toni choueiri
-
0:48
combining radiotherapy and io for patients with oligometastatic rcc
-
1:18
using radiotherapy to manage oligometastatic kidney cancer
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
3:04
pembrolizumab for non-clear cell rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
3:01
a phase iii trial of pembrolizumab as adjuvant treatment for renal cell carcinoma
-
4:20
neoadjuvant avelumab plus axitinib active in high-risk rcc | axel bex
-
0:35
the latest developments in adjuvant therapy for rcc
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:34
evolving role of pd-l1 as a biomarker
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
8:50
updated results of a clinical trial evaluating pembrolizumab axitinib for frontline adv rcc